Atlas Brown Inc. Acquires 2,929 Shares of Pfizer Inc. $PFE

Atlas Brown Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 3.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,732 shares of the biopharmaceutical company’s stock after acquiring an additional 2,929 shares during the quarter. Atlas Brown Inc.’s holdings in Pfizer were worth $1,933,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Trust Co of the South lifted its position in Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after acquiring an additional 441 shares in the last quarter. William B. Walkup & Associates Inc. lifted its holdings in shares of Pfizer by 1.2% during the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock valued at $1,044,000 after buying an additional 454 shares during the period. Members Trust Co lifted its holdings in shares of Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 467 shares during the period. Sutton Place Investors LLC lifted its holdings in shares of Pfizer by 5.6% during the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 472 shares during the period. Finally, MSH Capital Advisors LLC lifted its holdings in shares of Pfizer by 1.4% during the 1st quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company’s stock valued at $876,000 after buying an additional 485 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 3.8%

NYSE:PFE opened at $23.91 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The business has a fifty day moving average price of $24.79 and a 200-day moving average price of $24.27.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the business posted $0.60 EPS. Pfizer’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Morgan Stanley increased their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Bank of America increased their price target on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. HSBC lowered their price target on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Monday, May 19th. Finally, Berenberg Bank reduced their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.